BRENTWOOD, TN, August 27, 2024 / Biotech Newswire / -- Currax Pharmaceuticals LLC (“Currax”) today announced the results of a Cardiovascular Health Outcomes Analysis (HOA). The results showed there is no evidence of excess cardiovascular risk and no statistically significant difference in major adverse cardiovascular events (MACE) between CONTRAVE®/MYSIMBA® and the comparator group.(1) The study, presented by Dr.

田纳西州布伦特伍德（BRENTWOOD，TN），2024年8月27日/Biotech Newswire/--Currax Pharmaceuticals LLC（“Currax”）今天宣布了心血管健康结果分析（HOA）的结果。结果显示，没有证据表明心血管风险过高，CONTRAVE®/MYSIMBA®与对照组之间的主要不良心血管事件（MACE）无统计学差异。（1） 这项研究由Dr。

Dustin Burns at the International Society for Pharmacoepidemiology (ISPE) conference, held August 24-28th in Berlin, Germany, included more than 24,600 people with an average follow-up of four and a half years.“The study's results found no evidence of increase in cardiovascular risk among initiators of CONTRAVE, which is informative for healthcare providers and patients considering this treatment option for obesity,” said Dustin Burns, Ph.D., GStat, the presenting author and Senior Managing Scientist at Exponent who led the analysis.These results are consistent with the four previous randomized clinical trials, the previous LIGHT Trial, and more than ten years of post-marketing safety surveillance data with over 700,000 patient years of product usage.

8月24日至28日在德国柏林举行的国际药物流行病学学会（ISPE）会议上，达斯汀·伯恩斯（DustinBurns）参加了超过24600人，平均随访时间为四年半。“这项研究的结果没有发现CONTRAVE引发者心血管风险增加的证据，这对于考虑肥胖治疗选择的医疗保健提供者和患者来说是有益的，”该研究报告的作者、Exponent公司的高级管理科学家达斯汀·伯恩斯（DustinBurns）博士表示。这些结果与之前的四项随机临床试验，之前的LIGHT试验以及十多年的上市后安全监测数据（超过700000患者年的产品使用）一致。

These study results help to substantiate the cardiovascular safety profile of CONTRAVE/MYSIMBA and the ongoing INFORMUS trial.  In addition, the ongoing INFORMUS trial will address the regulatory post-marketing commitments and further characterize the long-term cardiovascular safety for patients taking CONTRAVE/MYSIMBA.

这些研究结果有助于证实CONTRAVE/MYSIMBA和正在进行的INFORMUS试验的心血管安全性。此外，正在进行的INFORMUS试验将解决上市后的监管承诺，并进一步表征服用CONTRAVE/MYSIMBA的患者的长期心血管安全性。

In January 2024, the first patient was enrolled in the INFORMUS trial, and to date there are over 1,800 patients randomized. 'We are honored to have Dr. Burns present these favorable findings at ISPE,” Michael Kyle, M.D., SVP Chief Medical Officer of Currax Pharmaceuticals said. “Achieving this mil.

2024年1月，第一名患者参加了INFORMUS试验，迄今为止，已有1800多名患者被随机分组。Currax Pharmaceuticals高级副总裁医学博士迈克尔·凯尔（MichaelKyle）说：“我们很荣幸能让伯恩斯博士在ISPE上展示这些有利的发现。”。“实现这一目标。